The clinical effect of two thrombolytic regimens in patients with arteriovenous fistula embolism

Abstract

Objective To observe the clinical effect of single urokinase and urokinase pump combined with low-molecular-weight Heparin in the treatment of autogenous arteriovenous fistula thrombolysis, and the influence on inflammatory factors [interleukin(IL)-1, IL-6, tumor necrosis factor-α (TNF-α)] and CD62p. Methods 20 hemodialysis patients hospitalized in our hospital for the treatment of thrombosis in fistula were selected . They were randomly divided into group A (n=10) and group B (n=10). The group A was treated by urokinase infusion, and the group B was treated with urokinase pump combined with low-molecular heparin respectively. Results Compared with that before thrombolysis, the blood flow rate was increased significantly while the IL-1, TNF-α and CD62p decreased significantly in the two groups after thrombolytic treatment, with statistically significant difference (P<0.05). Compared with the group A, the IL-1, IL-6 and CD62p in group B were decreased after thrombolytic therapy, with statistically significant difference (P<0.05). Conclusions Urokinase combined with low-molecular-weight heparin is better than single urokinase in the treatment of arteriovenous fistula thrombolysis, providing a theoretical basis for clinical fistula thrombolysis treatment. Key words: Urokinase-type plasminogen activator/AD; Heparin, low-molecular-weight/AD; Arteriovenous fistula; Arteriovenous fistula/CO; Thrombosis/CO/DT; Thrombolytic therapy